References
- Pérez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C et a/. Geographical and ecological analysis of resistance, coresis-tance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965–1972.
- Perez-Trallero E, Marimon JM, Gonzalez A, Garcia-Rey C, Aguilar L. Genetic relatedness of recently collected Spanish respi-ratory tract Streptococcus pneumoniae isolates with reduced sus-ceptibility to amoxicillin. Antimicrob Agents Chemother 2003; 47: 3637–3639.
- Garcia-de-Lomas J, Lerma M, Cebrian L et al. Cefditoren activity against H. influenzae with different ampicillin susceptibili-ty phenotypes. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006, Abstract E-111.
- MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001; 48: 17–28.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that growth aerobically; approved standard-6th edition. NCCLS M7-A6. NCCLS, Wayne, Pa., 2003.
- Alou L, Gimenez MJ, Sevillano D et al. A pharmacody-namic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. J Antimicrob Chemother 2006; 58: 349–358.
- Echeverria O, Alou L, Sevillano D et al. Pharma-codynamics of simulated total versus free-drug serum concentra-tions of a low versus a high protein bound 3rd generation oral cephalosporin (cefpodoxime versus cefditoren) against Streptococcus pneumoniae. J Chemother 2007; 2007; 19 (3): 288-294.
- Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther 1996; 18: 56–72.
- Sevillano D, Alou L, Aguilar L, Echevarria 0, Gimenez MJ, Prieto J. Azithromycin iv pharmacodynamic parameters predict-ing Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation. J Antimicrob Chemother 2006; 57: 1128-1133.
- Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to ery-thromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556–564.
- Perez-Trallero E, Marimon JM, Gonzalez A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoro-quinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41: 560–564.